{"nctId":"NCT00419393","briefTitle":"Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures","startDateStruct":{"date":"2007-12"},"conditions":["Epilepsy"],"count":190,"armGroups":[{"label":"Keppra XR (Levetiracetam XR)","type":"EXPERIMENTAL","interventionNames":["Drug: Keppra XR (Levetiracetam XR)"]}],"interventions":[{"name":"Keppra XR (Levetiracetam XR)","otherNames":["Keppra XR"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who were randomized into study N01280 \\[NCT00419094\\], and completed the 2 week up titration period\n\nExclusion Criteria:\n\n* Subjects who did not meet the inclusion/exclusion criteria for N01280 \\[NCT00419094\\]\n* Subjects who were discontinued prior to the end of titration period","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"75 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Who Experienced at Least 1 Treatment Emergent Adverse Event During the Actual Treatment Period (6 Months-2 Years)","description":"An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Experienced at Least 1 Serious Treatment Emergent Adverse Event During the Actual Treatment Period (6 Months-2 Years)","description":"A serious adverse event is any untoward medical occurrences in a subject administered study treatment, whether or not the event is related to treatment, with at least one of the follow outcomes: death, life-threatening, initial inpatient hospitalization or prolongation of hospitalization, significant or persistent disability/incapacity, congenital anomaly/birth defect, or an important medical event that may jeopardize the subject and require a medical/surgical intervention.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Prematurely Discontinuing Due to a Treatment-emergent Adverse Event During the Actual Treatment Period","description":"An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Remaining on Keppra XR Monotherapy From Study Entry Through 6 Months","description":"Among subjects in the Efficacy (EFF) population entering the study on Keppra XR monotherapy and exposed for at least 6 months, is the percentage of subjects remaining on monotherapy treatment for at least 6 months.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Remaining on Keppra XR Monotherapy From Study Entry Through 12 Months","description":"Among subjects in the Efficacy (EFF) population entering the study on Keppra XR monotherapy and exposed for at least 6 months, is the percentage of subjects remaining on monotherapy treatment for at least 12 months.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":22,"n":189},"commonTop":["Headache","Nasopharyngitis","Somnolence","Influenza","Dizziness"]}}}